Stockscreener 앱 받기
1.86
1.59%
-0.03
시간 외 거래:
1.92
0.06
+3.23%
전일 마감가:
$1.89
열려 있는:
$1.87
하루 거래량:
1.07M
Relative Volume:
0.75
시가총액:
$262.74M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-5.3143
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
-2.11%
1개월 성능:
+27.40%
6개월 성능:
+6.29%
1년 성능:
+9.41%
1일 변동 폭
$1.84
$1.95
1주일 범위
$1.785
$1.95
52주 변동 폭
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.86 | 262.74M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Renaissance Technologies LLC Grows Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 23.4% in April - Defense World
Was Compass Therapeutics Inc (CMPX)’s session last reading good? - uspostnews.com
JPMorgan Chase & Co. Acquires 227,864 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Inc’s Market Journey: Closing Weak at 1.90, Down -2.06 - DWinneX
Compass Therapeutics (NASDAQ:CMPX) Given Buy Rating at D. Boral Capital - Defense World
Compass Therapeutics (CMPX) Unveils Promising Data at AACR Annua - GuruFocus
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World
It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World
What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com
Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World
Compass Therapeutics Inc [CMPX] Insider GORDON CARL L sells 3,571,428 Shares – Latest News - knoxdaily.com
Compass Therapeutics begins biliary cancer trial with new drug By Investing.com - Investing.com Canada
Compass Therapeutics begins biliary cancer trial with new drug - Investing.com
Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer - Nasdaq
Compass Therapeutics Announces First Patient Dosed in an - GlobeNewswire
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer - TradingView
Compass Therapeutics Insider Sold Shares Worth $5,678,571, According to a Recent SEC Filing - marketscreener.com
Orbimed advisors sells $5.68 million in Compass Therapeutics shares - Investing.com Australia
Orbimed advisors sells $5.68 million in Compass Therapeutics shares By Investing.com - Investing.com South Africa
Compass Therapeutics director Carl Gordon sells $5.68 million in shares By Investing.com - Investing.com India
Compass Therapeutics director Carl Gordon sells $5.68 million in shares - Investing.com
Compass Therapeutics chief accounting officer acquires $28,400 in stock - Investing.com Australia
Compass Therapeutics chief accounting officer acquires $28,400 in stock By Investing.com - Investing.com India
Compass Therapeutics general counsel buys $30,800 in common stock By Investing.com - Investing.com India
Compass Therapeutics general counsel buys $30,800 in common stock - Investing.com
Compass Therapeutics Executives Increase Holdings - TradingView
Wedbush Research Analysts Lower Earnings Estimates for CMPX - The AM Reporter
HC Wainwright Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World
Leerink Partnrs Has Pessimistic Outlook of CMPX Q2 Earnings - Defense World
FY2028 EPS Estimates for Compass Therapeutics Cut by Wedbush - Defense World
Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform - Defense World
Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint - insights.citeline.com
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs - Defense World
Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital - The AM Reporter
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq
Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN
Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com
Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance
Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 - MarketScreener
Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Compass Therapeutics Inc 주식 (CMPX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
0.39%
3.66%
자본화:
|
볼륨(24시간):